Comparative yield of HCV RNA testing in blood donors screened by 2.0 versus 3.0 antibody assays

ObjectiveTo compare the reproducibility of 11 antibody assays for immunoglobulin (Ig) G and IgM myelin oligodendrocyte glycoprotein antibodies (MOG-IgG and MOG-IgM) from 5 international centers.MethodsThe following samples were analyzed: MOG-IgG clearly positive sera (n = 39), MOG-IgG low positive sera (n = 39), borderline negative sera (n = 13), clearly negative sera (n = 40), and healthy blood donors (n = 30). As technical controls, 18 replicates (9 MOG-IgG positive and 9 negative) were included. All samples and controls were recoded, aliquoted, and distributed to the 5 testing centers, which performed the following antibody assays: 5 live and 1 fixed immunofluorescence cell-based assays (CBA-IF, 5 MOG-IgG, and 1 MOG-IgM), 3 live flow cytometry cell-based assays (CBA-FACS, all MOG-IgG), and 2 ELISAs (both MOG-IgG).ResultsWe found excellent agreement (96%) between the live CBAs for MOG-IgG for samples previously identified as clearly positive or negative from 4 different national testing centers. The agreement was lower with fixed CBA-IF (90%), and the ELISA showed no concordance with CBAs for detection of human MOG-IgG. All CBAs showed excellent interassay reproducibility. The agreement of MOG-IgG CBAs for borderline negative (77%) and particularly low positive (33%) samples was less good. Finally, most samples from healthy blood donors (97%) were negative for MOG-IgG in all CBAs.ConclusionsLive MOG-IgG CBAs showed excellent agreement for high positive and negative samples at 3 international testing centers. Low positive samples were more frequently discordant than in a similar comparison of aquaporin-4 antibody assays. Further research is needed to improve international standardization for clinical care.

Download Full-text

Anti-GOR to screen HCV-RNA-positive blood donors

The Lancet ◽

10.1016/0140-6736(91)90533-u ◽

1991 ◽

Vol 338 (8763) ◽

pp. 391 ◽

Cited By ~ 3

Author(s):

Junnosuke Watanabe ◽

Chieko Matumoto ◽

Kusuya Nishioka ◽

Hiroshi Yoshizawa

Keyword(s):

Blood Donors ◽

Hcv Rna

Download Full-text

Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors

Transfusion ◽

10.1111/j.1537-2995.2006.00745.x ◽

2006 ◽

Vol 46 (3) ◽

pp. 469-475 ◽

Cited By ~ 40

Author(s):

Michael P. Busch ◽

Simone A. Glynn ◽

Susan L. Stramer ◽

Jennie Orland ◽

Edward L. Murphy ◽

...

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Blood Donors ◽

Hcv Rna

Download Full-text

Evaluation of HCV RNA by PCR and Signal-to-Cutoff Ratios of HCV Antibody Assays for Diagnosis of HCV Infection

Laboratory Medicine ◽

10.1093/labmed/lmaa074 ◽

2020 ◽

Author(s):

Myeong Hee Kim ◽

So Young Kang ◽

Woo In Lee ◽

Min Young Lee

Keyword(s):

Operating Characteristic ◽

Hcv Infection ◽

Hcv Rna ◽

Immunoblot Assay ◽

Receiver Operating Characteristic Curves ◽

Antibody Assays ◽

Recombinant Immunoblot Assay ◽

Hcv Antibody ◽

Polymerase Chain

Abstract Objective In this study, we assessed whether a hepatitis C virus (HCV) RNA test could replace recombinant immunoblot assay (RIBA) and reduce unnecessary supplemental tests as the signal-to-cutoff (S/Co) ratio from anti-HCV antibody (Ab) tests. Methods Anti-HCV Ab tests were performed to screen for HCV infections, and RIBA and real-time polymerase chain reaction were performed for HCV RNA to confirm HCV infection. Receiver operating characteristic curves were evaluated to determine the optimal S/Co ratios for predicting HCV infection. Results The cutoff value for the S/Co ratio was 3.63 for predicting RIBA results and 10.6 for predicting HCV RNA results. Our data suggested that an S/Co ratio ≥10.6 indicated a high risk of active HCV infection. An S/Co ratio of 3.63 to 10.6 needed further evaluation and repeat HCV RNA testing. No further testing was required for S/Co ratios <3.63 or ≥10.6. Conclusion We determined that the S/Co ratio of the anti-HCV Ab test provides useful information to confirm HCV infections, including the need for further laboratory testing or clinical follow-up.

Download Full-text

Expression Profiles of Exosomal MicroRNAs from HEV- and HCV-Infected Blood Donors and Patients: A Pilot Study

Viruses ◽

10.3390/v12080833 ◽

2020 ◽

Vol 12 (8) ◽

pp. 833 ◽

Cited By ~ 1

Author(s):

Karen McGowan ◽

Kenneth J. Simpson ◽

Juraj Petrik

Keyword(s):

Preliminary Data ◽

Blood Donors ◽

Viral Infections ◽

Expression Profiles ◽

Gradient Centrifugation ◽

Antiviral Treatment ◽

Hepatitis E ◽

Hcv Rna ◽

Host Immune Responses ◽

Exosomal Microrna

Exosomes seem to play an important role in hepatits C virus (HCV) and hepatitis E virus (HEV) infection by shielding their cargo from the host immune responses, with microRNAs being key exosomal components. Little is known about their involvement in a mixed HCV/HEV infection or at the early stages of infection, such as in asymptomatic blood donors (BDs). To obtain preliminary data, we have compared the exosomal microRNA expression profiles in four each of HCV RNA-positive, HEV RNA-positive and negative blood donors and four patients, one of whom was a rare patient with HCV/HEV co-infection. Exosomes were purified from sera by a combination of a precipitation and density gradient centrifugation and exosomal microRNA was analysed using Taqman array cards. Out of 33 deregulated miRNAs, miR-885-5p and miR-365 were upregulated in HCV BDs, miR-627-5p was downregulated in HCV BD and miR-221 was downregulated in HCV patients and BDs. In HEV infection, miR-526b appeared specifically downregulated. Six miRNAs (miR-628-3p, miR-194, miR-151-3p, miR-512-3p, miR-335 and miR-590) indicated a potential involvement in both infections. First time preliminary data on pre- and post-antiviral treatment exosomal microRNA profiles of the HEV/HCV co-infected patient revealed a pool of 77 upregulated and 43 downregulated miRNAs to be further investigated for their potential roles in these viral infections.

Download Full-text